Targets and Emerging Therapies for Schizophrenia

Targets and Emerging Therapies for Schizophrenia

by Jeffrey S. Albert
     
 

View All Available Formats & Editions

New and emerging directions in pharmaceutical research to better treat schizophrenia

Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating

Overview

New and emerging directions in pharmaceutical research to better treat schizophrenia

Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases.

Targets and Emerging Therapies for Schizophrenia presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined.

With contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia. Targets and Emerging Therapies for Schizophrenia:

  • Provides a comprehensive resource for neuro-drug discovery and the development of molecular targets for schizophrenia treatment
  • Draws from chemistry, biology, and pharmacology for more effective drug targeting and discovery
  • Explores a wide range of receptors and molecular targets, including dopamine, PDEs, and neuropeptides

With Targets and Emerging Therapies for Schizophrenia as their guide, drug discovery and development scientists have the information they need to advance their own research so that new, more effective treatments for schizophrenia will soon be a reality.

Editorial Reviews

Doody's Review Service
Reviewer: Michael Joel Schrift, DO, MA (Northwestern University Feinberg School of Medicine)
Description: It continues to be unfortunate that schizophrenia is studied as if it is a single disease. The current concept of schizophrenia is likely to include multiple phenotypically overlapping syndromes and diseases, and schizophrenia can no longer be considered a unitary entity. Any research that does not take this heterogeneity seriously has, in my opinion, outlived its usefulness. This book does not, for the most part, incorporate any issues of validity and heterogeneity and most of the chapters use the unitary concept as a default. The book is written and edited largely (but not entirely) by pharmaceutical industry scientists. Although the review of receptor pharmacology is helpful, I did not find that this book, as a whole, advanced my knowledge of psychosis in general and schizophrenia specifically.
Purpose: The purpose, according to the editors, is to "present the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics."
Audience: The intended audience, although not specifically stated, includes psychiatrists, psychiatric researchers, and psychopharmacological researchers.
Features: The chapters cover etiology and prevalence, dopamine agonists and phosphodiesterase inhibitors, receptor modulators, inhibitors, and targeting strategies for drug discovery. Each chapter ends with relevant citations of the scientific literature. The index is quite detailed.
Assessment: Because the book is authored by research scientists working in the pharmaceutical industry, I doubt clinicians would find it useful. I am sorry, but I cannot recommend it.
From the Publisher
“In summary, this book provides a timely and convenient reflection on schizophrenia drug discovery and development, which has been a major component of psychiatric drug research for several decades.”  (ChemMedChem, 1 March 2013)

Product Details

ISBN-13:
9780470322826
Publisher:
Wiley
Publication date:
07/10/2012
Pages:
494
Product dimensions:
6.30(w) x 9.30(h) x 1.00(d)

Meet the Author

JEFFREY S. ALBERT, PhD, is a Project Leader and Head of Lead Generation Chemistry in AstraZeneca's neuroscience department. He has authored or coauthored more than forty publications, mostly focusing on novel therapeutic targets involved in depression, schizophrenia, and Alzheimer's disease and on the development and application of fragment-based lead generation methodologies.

MICHAEL W. WOOD, PhD, is an External Collaborations Director in AstraZeneca's neuroscience unit where he is responsible for coordinating research to deliver novel therapeutics targeting schizophrenia as well as other neuroscience treatments. He has been focused on neuroscience drug discovery research for fifteen years.

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >